Additional Toxicities in GPRC5D-Directed Bispecifics for RRMM
Panelist discusses how, based on the patient achieving sCR with emerging oral, skin, and nail toxicities, panelist would recommend initiating supportive care, including oral hygiene protocols, topical treatments, and prophylactic nail care. These toxicities are generally less severe than those of BCMA-targeted bispecifics, which often present with more systemic CRS and neurotoxicity.
Video content above is prompted by the following:
- After the first month of treatment, the patient achieved stringent complete response (sCR) but is experiencing the following symptoms: oral, skin, and nail toxicities.
- What mitigation strategies would you initiate for this patient?
- How do those toxicities compare with those of other bispecifics (ie, BCMA-directed) in this space?
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
